Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Técnica de Aspiración Dual Continua con Sistema Zoom para Ictus (ADAPT 2 0)

11 de noviembre de 2026 actualizado por: Imperative Care, Inc.

Evaluación Clínica de la Técnica de Aspiración Dual Continua con el Sistema Zoom para Ictus (ADAPT 2.0)

This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

De observación

Inscripción (Estimado)

750

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Alabama
      • Huntsville, Alabama, Estados Unidos, 35801
        • Reclutamiento
        • Huntsville Hospital
        • Contacto:
          • Farrar Hickey
        • Investigador principal:
          • R. Dana Tomalty, MD
    • California
      • Walnut Creek, California, Estados Unidos, 94598
        • Reclutamiento
        • John Muir Health
        • Investigador principal:
          • Benjamin Yim, MD
        • Contacto:
          • Melenie Aaron
    • Florida
      • Tampa, Florida, Estados Unidos, 33606
        • Reclutamiento
        • University of South Florida
        • Investigador principal:
          • Maxim Mokin, MD
        • Contacto:
          • Kilaun Robinson
    • Georgia
      • Marietta, Georgia, Estados Unidos, 30060
        • Reclutamiento
        • Wellstar Kennestone Hospital
        • Contacto:
          • Autumn Lee
        • Investigador principal:
          • Ahmad Khaldi, MD
    • Louisiana
      • Lafayette, Louisiana, Estados Unidos, 70503
        • Reclutamiento
        • Ochsner Clinic Foundation (Lafayette)
        • Investigador principal:
          • Shail Thanki, MD
      • New Orleans, Louisiana, Estados Unidos, 70121
        • Reclutamiento
        • Ochsner Clinic Foundation
        • Investigador principal:
          • James Milburn, MD
        • Contacto:
          • Jessica Henry
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • Reclutamiento
        • University of Maryland
        • Investigador principal:
          • Jacob Cherian, MD
        • Contacto:
          • Katie Henry
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55407
        • Reclutamiento
        • Allina Health
        • Contacto:
          • Emeryth Beloy
        • Investigador principal:
          • Collin Torok, MD
    • New York
      • Albany, New York, Estados Unidos, 12208
        • Reclutamiento
        • Albany Medical College
        • Investigador principal:
          • Alexandra Paul, MD
        • Contacto:
          • Chelsey Large
      • Buffalo, New York, Estados Unidos, 14203
        • Reclutamiento
        • University at Buffalo Neurosurgery
        • Investigador principal:
          • Jason Davies, MD
        • Contacto:
          • Ellen Carl
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Weill Cornell Medicine
        • Contacto:
          • Hanah Hwang
        • Investigador principal:
          • Amol Mehta, MD
      • New York, New York, Estados Unidos, 10029
        • Reclutamiento
        • Icahn School of Medicine at Mount Sinai
        • Contacto:
          • Kevin Buttet
        • Investigador principal:
          • Michael T Caton, MD
      • Syracuse, New York, Estados Unidos, 13210
        • Reclutamiento
        • SUNY Upstate Medical Center
        • Contacto:
          • Saptarshi Prachi
        • Investigador principal:
          • Haydn Hoffman, MD
      • The Bronx, New York, Estados Unidos, 10467
        • Reclutamiento
        • Montefiore Medical Center
        • Contacto:
          • Genesis Liriano
        • Investigador principal:
          • Amanda Baker, MD
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45220
        • Reclutamiento
        • TriHealth Good Samaritan Hospital
        • Investigador principal:
          • Andrew Ringer, MD
        • Contacto:
          • Mehnaaz Ali
      • Columbus, Ohio, Estados Unidos, 43221
        • Reclutamiento
        • The Ohio State University Wexner Medical Center
        • Investigador principal:
          • Patrick Youssef, MD
        • Investigador principal:
          • Shahid Nimjee, MD
        • Contacto:
          • Edward Belizaire
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Reclutamiento
        • University of Oklahoma, Health Science Center
        • Investigador principal:
          • Hakeem Shakir, MD
        • Contacto:
          • Sanaa Hameed
    • South Carolina
      • Greenville, South Carolina, Estados Unidos, 29605
        • Reclutamiento
        • Prisma Health - Upstate
        • Contacto:
          • Shawn Manos
        • Investigador principal:
          • Jan Vargas Machaj, MD
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37902
        • Reclutamiento
        • Fort Sanders Regional Medical Center
        • Contacto:
          • Cameron Carter
        • Investigador principal:
          • Robert Hixson, MD
      • Memphis, Tennessee, Estados Unidos, 38120
        • Reclutamiento
        • Semmes Murphey Foundation
        • Investigador principal:
          • Lucas Elijovich, MD
        • Contacto:
          • Wendell Barnett
    • Texas
      • Kingwood, Texas, Estados Unidos, 77339
        • Reclutamiento
        • HCA Houston Healthcare Kingwood
        • Investigador principal:
          • Mohamad Ezzeldin, MD
        • Contacto:
          • Swathi Potla
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • Methodist Healthcare System of San Antonio
        • Contacto:
          • Samantha Franklin
        • Investigador principal:
          • Lee Birnbaum, MD
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • University of Texas Science Health Center at San Antonio
        • Investigador principal:
          • Justin Mascitelli, MD
        • Contacto:
          • Athena Lazaris-Conner
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Reclutamiento
        • University of Utah
        • Contacto:
          • Andrew Grandemange
        • Investigador principal:
          • Robert Rennert, MD
    • Virginia
      • Falls Church, Virginia, Estados Unidos, 22042
        • Reclutamiento
        • Inova Fairfax Medical Campus
        • Contacto:
          • Lauren Monroe
        • Investigador principal:
          • James McEachern, MD
    • Washington
      • Spokane, Washington, Estados Unidos, 99204
        • Reclutamiento
        • Providence Sacred Heart Medical Center and Children's Hospital
        • Contacto:
          • Kyle Kramer
        • Investigador principal:
          • Christopher Zylak, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.

Descripción

Inclusion Criteria:

  1. Subject is ≥ 18 years of age
  2. Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
  3. Pre-stroke mRS 0-2
  4. Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use

Exclusion Criteria:

  1. Subjects with a life expectancy of less than 6 months
  2. Female subject who is known to be pregnant at time of admission
  3. Any intracranial hemorrhage in the qualifying head CT or MRI
  4. Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
  5. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
  6. Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)

The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets.

Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)

Otros nombres:
  • ADAPT 2.0
  • Trombectomía por aspiración para accidente cerebrovascular
  • Aspiración dual continua
  • Trombectomía por aspiración neurovascular

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Periodo de tiempo: End of procedure

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

End of procedure
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Periodo de tiempo: End of procedure

Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator

End of procedure

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Periodo de tiempo: Intraprocedural

The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique.

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

Intraprocedural
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Periodo de tiempo: Intraprocedural

Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs

Intraprocedural
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Periodo de tiempo: Intraprocedural

Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs

Intraprocedural
Rate of rescue therapy
Periodo de tiempo: Intraprocedural

Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c.

Intraprocedural
Rate of functional independence (mRS 0-2) at 90 days
Periodo de tiempo: 90 days post-procedure

Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days

mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome

90 days post-procedure
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Periodo de tiempo: Intraprocedural

Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

Intraprocedural
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Periodo de tiempo: 24-hour post-procedure

Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria

24-hour post-procedure
90-day all-cause mortality
Periodo de tiempo: 90 days post-procedure

Rate of all-cause mortality through 90 days post-procedure

90 days post-procedure
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Periodo de tiempo: Intraprocedural

Independently adjudicated rate of Serious Adverse Events related to study device

Intraprocedural

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: David Fiorella, MD, Stony Brook University
  • Investigador principal: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
  • Investigador principal: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
  • Investigador principal: Maxim Mokin, MD, University of South Florida

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

24 de marzo de 2026

Finalización primaria (Estimado)

31 de marzo de 2030

Finalización del estudio (Estimado)

1 de junio de 2030

Fechas de registro del estudio

Enviado por primera vez

17 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de marzo de 2026

Publicado por primera vez (Actual)

25 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ICI-2025-003

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .